OncoMatch/Clinical Trials/NCT01949129
Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia
Is NCT01949129 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2/3 trial studies multiple treatments for acute lymphoblastic leukaemia.
Treatment: VP16 · Thiotepa · Treosulfan · Fludarabine · Busulfan · ATG Thymoglobulin · Cyclophosphamide · Grafalon — The ALL SCTped 2012 FORUM is a multinational, multi-centre, controlled, prospective phase III study for the therapy and therapy optimisation for children and adolescents with ALL in complete morphological remission (CR, less than 5% bone marrow blasts, no blasts in cerebrospinal fluid, no other extramedullary leukemia), who have an indication for HSCT with a myeloablative conditioning regimen. The stratification of patients in first and following remissions according to the individual transplantation modalities rests upon an indication for allogeneic HSCT and the availability of a suitable donor within the individual transplantation groups.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Cancer type
Acute Lymphoblastic Leukemia
Disease stage
Required: Stage COMPLETE REMISSION
Demographics
Prior therapy
Cannot have received: stem cell transplant
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT01949129 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior stem cell transplant disqualifies patients from enrollment.
What disease stage is eligible?
Stage COMPLETE REMISSION is required.
Is there an age limit?
Yes. Patients must be 18 years or younger and at least 0 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages